In addition, Baghaee et al. evaluated the effect of IMODTM on inflammatory bowel disease in rats and reported that the medication significantly decreased TNF-α and IL-1β levels, resulting in a decrease in macroscopic tissue damage [12]. Here, IL1B is linked to inflammatory bowel disease.